RxDoctor Payments Data

Nicole Apple, OD

Optometrist · Southern Pines, NCNPI 1679821235

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 28 payments — averaging $42.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$662
  • Bausch & Lomb Americas Inc.$238
  • AbbVie$146
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$43
  • Johnson & Johnson Vision Care, Inc.$40
  • Sun Pharmaceutical Industries Inc.$28
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$1,15998%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 50th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$150,265
Medicare patients
713
Services billed
1,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine124$172,143
XiidraLifitegrast38$49,173
LumiganBimatoprost76$29,262
RocklatanNetarsudil Mesylat/Latanoprost36$25,522
MieboPerfluorohexyloctane/Pf28$20,700
VyzultaLatanoprostene Bunod36$18,209
Alphagan PBrimonidine Tartrate39$10,458
CombiganBrimonidine Tartrate/Timolol30$10,417
CequaCyclosporine16$9,472
RhopressaNetarsudil Mesylate18$8,700
Latanoprost518$6,011
SimbrinzaBrinzolamide/Brimonidine Tart27$5,704
Lotemax SmLoteprednol Etabonate19$5,482
Cyclosporine15$5,420
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$4,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$146$222,280269 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$238$88,081102 claims
Sun Pharmaceutical Industries Inc.Cequa$28$9,47216 claims
AlconSimbrinza$662$5,70427 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$43$5,48219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →